Creso Pharma (ASX:CPH) shares up 30pc amid speculation on U.S. cannabis bill, page-1638

I know what you mean. I'm on a single 24 month subscription to their Extreme Opportunities advisor service and have access to a suite of reports and recommendations.

I roll my eyes when they report on their own held stocks like BigTinCan. I won't be renewing my subscription.

However they do offer decent articles on stocks that they don't hold, like CPH. If you search CPH and look at all of the old articles they've written, it's clear that their advisors do not hold and offer unbiased reports.